Trial Radar AI

Laten we klinische studies bespreken en verkennen waarbij Arcutis Biotherapeutics als hoofdsponsor of partner betrokken is.

Ik help u graag met vragen over gezondheidsaandoeningen, behandelingen en het vinden van klinische studies in uw buurt.
27 klinische studies
Studietitel
Status
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 NCT07453602
Rekruterend
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis NCT07340216
Rekruterend
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV) NCT07105254
Rekruterend
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa NCT07077902
Rekruterend
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis NCT06998056
Afgerond
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) NCT05028582
AfgerondResultaten gepubliceerd
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) NCT04973228
AfgerondResultaten gepubliceerd
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) NCT04845620
AfgerondResultaten gepubliceerd
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo NCT04811131
BeëindigdResultaten gepubliceerd
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE) NCT04804605
AfgerondResultaten gepubliceerd
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) NCT04773600
AfgerondResultaten gepubliceerd
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-I) NCT04773587
AfgerondResultaten gepubliceerd
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) NCT04746911
Afgerond
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) NCT04655313
AfgerondResultaten gepubliceerd
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis NCT04445987
AfgerondResultaten gepubliceerd
Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema NCT04378569
AfgerondResultaten gepubliceerd
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (DERMIS-OLE) NCT04286607
Afgerond
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis (MUSE) NCT04279119
Afgerond
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (DERMIS-2) NCT04211389
AfgerondResultaten gepubliceerd
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (DERMIS-1) NCT04211363
AfgerondResultaten gepubliceerd
Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema NCT04156191
Afgerond
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis NCT04128007
AfgerondResultaten gepubliceerd
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis NCT04091646
AfgerondResultaten gepubliceerd
Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis NCT03916081
AfgerondResultaten gepubliceerd
Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis NCT03764475
AfgerondResultaten gepubliceerd
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis (ARQ-151-201) NCT03638258
AfgerondResultaten gepubliceerd
Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis NCT03392168
AfgerondResultaten gepubliceerd